The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
Open Access
- 1 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (1), 30-38
- https://doi.org/10.1093/eurheartj/ehr504
Abstract
Patients with chronic heart failure (CHF) show impaired health-related quality of life (HRQoL), an important target for therapeutic intervention. Impaired iron homeostasis may be one mechanism underlying the poor physical condition of CHF patients. This detailed subanalysis of the previously published FAIR-HF study evaluated baseline HRQoL in iron-deficient patients with CHF and the effect of intravenous ferric carboxymaltose (FCM) on HRQoL. FAIR-HF randomized 459 patients with reduced left ventricular ejection fraction and iron deficiency, with or without anaemia, to FCM or placebo (2:1). Health-related quality of life was assessed at baseline and after 4, 12, and 24 weeks of therapy using the generic EQ-5D questionnaire and disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ). Baseline mean Visual Analogue Scale (VAS) score was 54.3 ± 16.4 and KCCQ overall summary score was 52.4 ± 18.8. Ferric carboxymaltose significantly improved VAS and KCCQ (mean differences from baseline in KCCQ overall, clinical and total symptom scores, P< 0.001 vs. placebo) at all time points. At Week 24, significant improvement vs. placebo was observed in four of the five EQ-5D dimensions: mobility (P= 0.004), self-care (P< 0.001), pain/discomfort (P= 0.006), anxiety/depression (P= 0.012), and usual activity (P= 0.035). Ferric carboxymaltose improved all KCCQ domain mean scores from Week 4 onward (P≤ 0.05), except for self-efficacy and social limitation. Effects were present in both anaemic and non-anaemic patients. HRQoL is impaired in iron-deficient patients with CHF. Intravenous FCM significantly improved HRQoL after 4 weeks, and throughout the remaining study period. The positive effects of FCM were independent of anaemia status.Keywords
This publication has 31 references indexed in Scilit:
- Iron Deficiency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey IIICirculation: Heart Failure, 2011
- Myocardial and Systemic Iron Depletion in Heart Failure: Implications for Anemia Accompanying Heart FailureJournal of the American College of Cardiology, 2011
- Self‐care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2011
- Iron deficiency: an ominous sign in patients with systolic chronic heart failureEuropean Heart Journal, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyThe New England Journal of Medicine, 2009
- Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR‐HF) study: a randomized, placebo‐controlled study of intravenous iron supplementation in patients with and without anaemiaEuropean Journal of Heart Failure, 2009
- Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart FailureJournal of the American College of Cardiology, 2006
- The effect of beta‐blocker therapy on quality of life in heart failure patients: a systematic review and meta‐analysisPharmacoepidemiology and Drug Safety, 2006
- Monitoring clinical changes in patients with heart failure: A comparison of methodsAmerican Heart Journal, 2005
- Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trialBMJ, 2003